Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined immunosuppressive therapy in systemic sclerosis-associated interstitial lung disease: Phenotypes matter.

Autoimmunity reviews - 1 Aug 2026

Marchetti Marta, Motta Francesca, Tonutti Antonio, Selmi Carlo, De Santis Maria

Abstract excerpt

Current evidence suggests that combined immunosuppressive therapy with mycophenolate mofetil (MMF)-or less frequently cyclophosphamide (CYC)- plus a biologic agent-such as rituximab (RTX) or tocilizumab (TCZ)-is a rational and effective strategy in inflammatory, progressive systemic sclerosis (SSc)-associated interstitial lung disease (ILD), particularly when ILD coexists with other SSc domains encompassing skin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Immunosuppressive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Diseases, Interstitial

Share to Mycophenolic Acid

Share to Phenotype

Share to Rituximab

Share to Scleroderma, Systemic

Share to Treatment Outcome

Source

Identifiers

PMID: 42214802
DOI: 10.1016/j.autrev.2026.104092

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined immunosuppressive therapy in systemic sclerosis-associated interstitial lung disease: Phenotypes matter.PMID 42214802Read ↗

Connective Tissue Disease-Associated Interstitial Lung Diseases: Unresolved Issues.Semantic proximity Read ↗

Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.Semantic proximity Read ↗

Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy.Semantic proximity Read ↗

Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease.Semantic proximity Read ↗

Clinical Phenotypes of Patients With Systemic Sclerosis With Distinct Molecular Signatures in Skin.Semantic proximity Read ↗

Novel classifications for systemic sclerosis: challenging historical subsets to unlock new doors.Semantic proximity Read ↗

Anti-PM-Scl antibodies-positive patients encompass three different groups with distinct prognoses.Semantic proximity Read ↗

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.Semantic proximity Read ↗

Shaping the landscape of interstitial lung disease in idiopathic inflammatory myopathies: state of the art, evidence gaps and a need for clinical trials.Semantic proximity Read ↗

Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union.Semantic proximity Read ↗

Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management.Semantic proximity Read ↗

The differential role of SSa/SSb and Ro52 antibodies in defining clinical phenotypes in idiopathic inflammatory myopathies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.